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Gastriccancerisoneofthemostcommoncausesofcancer-related deathworldwide.Surgical resection withlymphnodedissection
is the only potentially curative therapy for gastric cancer. However, the appropriate extent of lymph node dissection accompanied
by gastrectomy for cancer remains controversial.In EastAsian countries, especially in Japanand Korea, D2 lymph node dissection
has been regularly performed as a standard procedure. In Western countries, surgeons perform gastrectomy with D1 dissection
onlybecause D2isassociatedwithhighmortalityandmorbiditycomparedtothoseassociatedwithD1alonebutdoesnotimprove
the 5-year survival rate. However, more recent studies have demonstrated that western surgeons can be trained to perform D2
lymphadenectomies on western patients with a lower morbidity and mortality. When extensive D2 lymph node dissection is
preformed safely, there may be some beneﬁt to D2 dissection even in western countries. In this paper, we present an update on the
current literature regarding the extent of lymphadenectomy for advanced gastric cancer.
1.Introduction
Gastric cancer is one of the most common causes of death
worldwide [1]. Although the prognosis of patients with
advanced gastric cancer has improved with the introduction
of eﬀective chemotherapy [2] or adjuvant radiotherapy [3],
surgical resection remains the primary therapeutic modality
for curable advanced cancer. With regard to surgical pro-
cedure, dissection of regional LN is regarded an important
part of en bloc resection for gastric cancer. However, there
are signiﬁcant diﬀerences in the extent of lymphadenectomy
preformed by surgeons in diﬀerent countries.
In Japan, D2 dissection has been recommended as stan-
dard practice since the 1960s [4]. East Asian surgeons, espe-
cially Japanese and Korean surgeons, routinely performed
gastrectomy with D2 dissection. However, most Western
surgeons perform gastrectomy with only D1 dissection,
because D1 was associated with less mortality and morbidity
than D2 in prospective randomized trials preformed in
the Netherland and the UK concluded that there was no
survival beneﬁt for D2 over D1 lymph node dissection
[5, 6]. However, there were signiﬁcant problems with these
studies, including a high morbidity and mortality rate in
the D2 group associated with inadequate surgical training,
with inadequate dissection of D2 and with the frequent
performance of distal pancreatectomy and splenectomy in
the D2 group, which is now considered unnecessary [7].
More recent studies have demonstrated that western
surgeons at experienced centers can be trained to perform
D2 gastrectomy for selected western patients with low
morbidity and mortality [8–10]. There may be some beneﬁts
to D2 gastrectomy when performed safely, but this assertion
requires further validation to establish the global standard in
gastrectomy.
In this paper, we describe an update on the current
literature regarding the extent of lymphadenectomy for
advanced gastric cancer.
2.Grouping ofLymphNodes
The lymph nodes of the stomach have been arranged into
a very useful classiﬁcation by the Japanese Gastric Cancer
Association (JGCA) [11, 12]( Table 1, Figure 1).2 International Journal of Surgical Oncology
Table 1: Regional lymph nodes.
No. 1 Right paracardial LN
No. 2 Lest paracardial LN
No. 3a LN along the left gastric vessels
No. 3b LN along the right gastric vessels
No. 4sa LN along the short gastric vessels
No. 4sb LN along the left gastroepiploic vessels
No. 4d LN along the right gastroepiploic vessels
No. 5 Suprapyloric LN
No. 6 Infrapyloric LN
No. 7 LN along the left gastric artery
No. 8a LN along the commonhepatic artery (anterosuperior
group)
No. 8b LN along the commonhepatic artery (posterior group)
No. 9 LN along the celiac artery
No. 10 LN at the splenic hilum
No. 11p LN along the proximal splenic artery
No. 11d LN along the distal splenic artery
No. 12a LN in the hepatoduodenal ligament (along the hepatic
artery)
No. 12b LN in the hepatoduodenal ligament (along the bile
duct)
No. 12p LN in the hepatoduodenal ligament (behind the portal
vain)
No. 13 LN on the posterior surface of the pancreatic head
No. 14v LN along the superior mesenteric vein
No. 14a LN along the superior mesenteric artery
No. 15 LN along the middle colic vessels
No. 16a1 LN in the aortic hiatus
No. 16a2
LN around the abdominalaorta (from the upper
margin of the celiac trunk to the lower margin of the
left renal vein)
No. 16b1
LN around the abdominalaorta (from the lower
margin of the left renal vein to the upper margin of the
inferior mesenteric artery)
No. 16b2
LN around the abdominalaorta (from the upper
margin of the inferior mesenteric artery to the aortic
bifurcation)
No. 17 LN on the anterior surface of the pancreas head
No. 18 LN along the inferior margin on the pancreas
No. 19 Infradiaphragmatic LN
No. 20 LN in the esophageal hiatus of the diaphragm
No. 110 Paraesophageal LN in the lower thorax
No. 111 Supradiaphragmatic LN
No. 112 Posterior mediastinal LN
According to this classiﬁcation, lymph nodes surround-
ing stomach are divided into 20 stations and these are
classiﬁed into three groups depending upon the location
of the primary tumor. This grouping system is based on
the results of studies of lymphatic ﬂow at various tumor
sites, together with the observed survival associated with
metastasis to each nodal station [13]. In this grouping
Table 2: Depth of tumor invasion (T)—Japaneseclassiﬁcationand
TNN.
Depth of tumor
invasion (T)
Japanese
classiﬁcation
(JC: 13th
edition)
TNM
classiﬁcation
(6th edition)
JC (14th edi-
tion)/TNM
(7th edition)
Mucosa and/or
muscularis
mucosa (M)
T1 (M) Tis/T1 Tis/T1a
Submucosa
(SM) T1 (SM) T1 T1b
Muscularis
propria (MP) T2 (MP) T2a T2
Subserosa (SS) T2 (SS) T2b T3
Penetration of
serosa (SE) T3 T3 T4a
Invasion of
adjacent
structures (SI)
T4 T4 T4b
Table 3:Extent oflymphnode metastasis(N)—Japaneseclassiﬁca-
tion and TNN classiﬁcation.
N
category
Japanese
classiﬁcation
(JC: 13th
edition)
TNM
classiﬁcation
(6th edition)
JC (14th
edition)/TNM
(7th edition)
N0
No evidence of
LN metastasis
No evidence of
LN metastasis
No evidence of
LN metastasis
N1
Metastasis to
only Group 1
LN
Metastasis in 1
to 6 regional
LNs
Metastasis in 1
to 2 regional
LNs
N2
Metastasis to
Group 2 LN, but
no metastasis to
Group 3 LN
7–15 nodes 3–6 nodes
N3
Metastasis to
Group 3 LN
16 or more
nodes
7 or more nodes
N3a: 7–15 nodes
N3b: 16 or more
nodes
LN: lymph node.
system, the most perigastric LNs (stations nos. 1–6) are
deﬁned as group 1, whereas the nodes along the left gastric
artery (station no. 7), common hepatic artery (station no.
8), celiac axis (station no. 9), splenic artery (station no. 11)
and proper hepatic artery (station no. 12) are deﬁned as
group 2. Minor modiﬁcations of this grouping system are
necessary accordingtothelocation ofthe primary tumor.D1
gastrectomy is deﬁned as dissection of all the Group 1 nodes,
a n dD 2i sd e ﬁ n e da sd i s s e c t i o no fa l lt h eG r o u p1a n dG r o u p
2n o d e s .
Recently, new Japanese Classiﬁcation of Gastric Carci-
noma [12] and guideline for Diagnosis and Treatment of
Carcinoma of the Stomach [14] edited by the Japanese
Gastric Cancer Society were published in May and October,
2010tomatch tothestandard ofTNMclassiﬁcation ofUICC
[15, 16]( T a b l e s2 and 3).International Journal of Surgical Oncology 3
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Figure 1: Lymph node station numbers according to the Japanese classiﬁcation of gastric cancer of the 14th edition reproduced form [12]
with permission.
In this classiﬁcation, the extent of LN metastasis is
divided into three groups according to the number of
metastatic LN, not to the N-number of the extent of LN
metastasis.
Moreover in this guideline, the main modiﬁcation about
lymph node dissection is that selection of D1 or D2
dissection is prescribed by the kind of gastrectomy, for
example, total gastrectomy or distal gastrectomy, not by
the location of the primary tumor. It is provided that D1
gastrectomy includes the dissection of the nodes along the
left gastric (station no. 7) as well as the perigastric lymph
nodes(stations nos.1–6),regardless of thelocationoftumor.
LNs along the superior mesenteric vein (station no. 14v) are
eliminated from D2 dissection for tumor in the lower third
of the stomach.
In other words, D1 distal gastrectomy consists of LN
dissection of station nos. 1, 3, 4sb, 4d, 5, 6, and 7 and D1
total gastrectomy includes station nos. 1–6 and 7 (Figure 2).
In Japan, although the surgical procedure is performed
according to the new guidelines, standard surgery for cN1
or T2 and more cases is deﬁned as gastrectomy with D2
dissection.
3. D1 versusD2
In Japan, D2 dissection was introduced in the 1960’s and
gastrectomy with D2 dissection has been regarded as a
safe surgical procedure and performed regularly in ordinary
general hospitals [4]. Therefore, in Japan, a clinical trial
comparing D1 versus D2 would be considered unethical
today.
However, whether D2 LN dissection in radical gastrec-
tomy should be routinely performed is still unclear in the
world.
Based on the results of several RCTs comparing D1
and D2/D3 dissection performed in western countries, D2
dissection is not recommendedbecauseD2is associated with
high morbidity and mortality rate.
Two large-scale RCTs wereperformed by the Dutch
Gastric Cancer Group [5, 17–19] and Medical Research
Council Gastric Cancer Surgical Group [6, 20]( Table 4).
The RCT by the Dutch group was performed between 1989
and 1993 and involved 711 patients from 80 hospitals but
excluded 285 patients who had received palliative treatment
[5]. The RCT by the British group was performed between
1987 and 1994 and involved 400 patients but excluded
337 patients based on staging laparoscopy demonstrating
advanced disease [6].
The stage distribution in the Dutch RCT was slightly less
advanced than that in the British study; UICCstage I tumors
comprised 43% and 35% of the total, respectively, and T3
tumors comprised 44 and 27%.
In the Dutch trial, D2 patients demonstrated higher
postoperative morbidity (43% versus 25% for D1: P<. 001)
and higher morbidity (10% versus 4% for D1: P<. 004).
Overall 5-year survival rates were similar in the D1 and D2
groups (45% for D1 and 47% for D2).
The hazard ratio (HR) comparing the risk of death
within 5 years after D2 surgery to that of 5 years after D1
surgery was 1.00 (95% conﬁdence interval (95% CI), 0.82–
1.22) [5]. However, at 11 years, survival rates were 30% for
D1 and 35% for D2 (P = .53). When hospital deaths were
excluded, survival rates were 32% for D1 (n = 365) and
39% for D2 (n = 299) and the relative risks of these patients
favored the D2 surgery group (P = .07) [17].
Low-quality surgery due to a very low hospital volume
could explain why D2 surgery was not beneﬁcial, along
with high hospital mortality in that series. About 50% of
the patients in the D2 group did not undergo lymph node
dissection at all stations that should have been resected.
However, 6% of the patients in the D1 group underwent
dissection of more stations that would not been resected
in D1 surgery. These factors could have led to the limited
diﬀerence in outcomes, between D1 and D2 surgery [18].4 International Journal of Surgical Oncology
Table 4: Randomized controlled trials comparing D1 with D2/D3.
Study Country Comparison Postoperative
morbidity
Postoperative
mortality 5-year survival
Dutch trial
(1989–1993) Netherlands D1 (n = 380)
D2 (n = 331)
25%
43%
(P<. 001)
4%
10%
(P = .004)
45%
47%
HR 1.00
(95% CI, 0.82–1.22)
MRC trial
(1987–1994) UK D1 (n = 200)
D2 (n = 200)
28%
46%
(P<. 001)
6.5%
13%
(P = .04)
35%
33%
HR 1.10
(95% CI, 0.87–1.39)
Taiwanese trial
(1993–1999) Taiwan D1 (n = 110)
D3 (n = 111)
7.3%
17.1%
(P = .012)
0%
0%
53.6%
59.5%
HR 0.49
(95% CI, 0.32–0.77)
IGCSG trial
(1999–2002) Italy D1 (n = 76)
D2 (n = 86)
10.5%
16.3%
(P<. 029)
0%
1.3%
(N.S)
Under analysis
Recently, 15-year follow-up results of a randomized
nationwide Dutch D1D2 trial were reported. The overall
15-year survival was 21% (82 patients) for the D1 group
and 29% (92 patients) for the D2 group (P = .34). The
gastric-cancer related death rate was signiﬁcantly higher in
the D1 group (48%, 182 patients) compared with that in the
D2 group (37%, 123 patients), whereas death due to other
diseases was similar in both groups [19].
Theauthorsindicatedintheinterpretationthatbecausea
safer, spleen-preserving D2 resection technique had become
available in high-volume centers, D2 lymphadenectomy
should be the recommended surgical approach for patients
with resectable (curable) gastric cancer.
In the British study, postoperative complications were
signiﬁcantly higher in the D2 group (46%) than in the D1
group (28%; P<. 001), and the postoperative mortality was
also signiﬁcantly higher in the D2 group (13%) than in the
D1 group (6.5%; P = .04) [6].
In this study, splenectomy was performed for many
patientswith distal gastrectomy and pancreaticosplenectomy
was carried out in 56% of patients allocated to the D2
group and 4% of the D1 group. The high frequency of
postoperative complications was inﬂuenced by the excessive
surgery, which contributed to a misunderstanding of the
deﬁnition of D2 gastrectomy deﬁned by the Japanese Gastric
Cancer Association. The 5-year survival rate was 33% in
the D1 group and 35% in the D2 group, which did not
signiﬁcantly diﬀer between the two groups [20].
Unlikethese two large European trials, the Italian Gastric
Cancer Study Group (IGCSG) has shown the safety of D2
dissection with pancreas preservation in a one-arm phase
I-II trial [9]. Between 1994 and 1996, 191 eligible patients
were entered in the study. The overall morbidity rate was
20.9%. Surgical complications were observed in 16.7% of
patients and reoperation was necessary in six patients and
was successful in all cases. The overall hospital mortality rate
was 3.1%; it was higher after total gastrectomy (7.46%) than
after distal gastrectomy (0.8%). This study concluded that
postoperative morbidity and mortality rates were favorably
comparable to those reported after the standard Western
gastrectomy and that the more extensive Japanese procedure
with pancreas preservation can be regarded as a safe radical
treatment for gastric cancer in selected Western patients
treated at experienced centers.
A small-scale RCT comparing of the morbidity and
mortality of D1 to D2 gastrectomy was performed by IGCSG
[10].
Of 162 patients randomized, 76 were allocated to D1
and 86 to D2 gastrectomy. The overall postoperative mor-
bidity rate was 13.6%. Complications developed in 10.5%
of patients after D1 and in 16.3% of patients after D2
gastrectomy. This diﬀerence was not statistically signiﬁcant
(P<. 29). The overall postoperative mortality rate was
0.6% (one death); it was 1.3% after D1 and 0% after D2
gastrectomy. This study conﬁrmed that, at very experienced
centers, morbidity and mortality after extended gastrectomy
c o u l db ea sl o wa st h o s ea f t e rD 1g a s t r e c t o m y .
Another single-institutional small-scale RCT has
reported from Taiwan that there were no signiﬁcant
diﬀerences in the postoperative and mortality between
patients undergoing D3 and D1 gastrectomy [21, 22]. This
was the only trial that showed a signiﬁcantly higher 5-year
disease-speciﬁc survival in patients with D3 surgery than in
those with D1 surgery (Table 4).
Therefore, D2 gastrectomy is becoming accepted as a
safe treatment for gastric cancer at experienced centers, in
western countries.
4. D2 versusD3
In Japan, gastrectomy with more radical extended lym-
phadenectomy had been performed since 1980’s at many
specialized centers in order to improve the prognosis of
patientswithadvanced gastric cancer[23–26].The incidence
of microscopic metastasis in the paraaortic nodes (section
no. 16) in patients with gastrectomy undergoing D3 lymph
node dissection ranged from 6% to 33%, and the 5-yearInternational Journal of Surgical Oncology 5
Table 5: Randomized controlled trials comparing D2 with D2 plus para-aortic lymph nodes.
Study Country Comparison Postoperative
morbidity
Postoperative
mortality 5-year survival
JCOG trial
(1995–2001) Japan
D2 (n = 263)
D2+ PALN
(n = 260)
20.9%
28.1%
(P = .067)
0.8%
0.8%
(P = .99)
69.2%
70.3%
HR 1.03
(95% CI, 0.77–1.37)
Polish trial
(1999–2003) Poland
D2 (n = 141)
D2+ PALN
(n = 134)
27.7%
21.6%
(P = .248)
4.9%
2.2%
(P = .37)
Under analysis
East Asian trial
(1995–2002)
Japan, Korea,
and Chinese
Taiwan area
D2 (n = 135)
D2+ PALN
(n = 134)
26%
39%
(P = .023)
0.7%
3.7%
(P = .107)
52.6%
55.4%
(P = .801)
D2: gastrectomy with D2 lymph node dissection. PALN: para-aortic lymph node dissection.
survival rate had been reported to range from 12% to 23% in
patientsundergoinggastrectomy withD3dissection.Extend-
ing these previous ﬁndings regarding the favorable results
of D3 dissection, the Japanese Clinical Oncology Group
(JCOG) conducted a randomized clinical trial between 1995
and 2001 to compare D2 gastrectomy alone with D2 plus
paraaortic lymph node dissection (PAND) [27]. A total
of 523 patients with T2b, T3, and T4 gastric cancer were
registered and randomly assigned to D2 alone group (263
patients) or D2 plus PAND group (260 patients).
The rates of surgery-related complications among
patients assigned to D2 lymphadenectomy alone and those
assigned to D2 lymphadenectomy plus PAND were 20.9%
and 28.1%, respectively (P = .07). There were no signiﬁcant
diﬀerences between the two groups in the frequencies of
anastomotic leakage, pancreatic ﬁstula, abdominal abscess,
pneumonia, or death from any cause within 30 days after
surgery (the mortality was 0.8% in each group). The 5-year
overall survival rate was 69.2% for the group assigned to D2
lymphadenectomyaloneand70.3%forthegroupassigned to
D2 lymphadenectomy plus PAND;the hazard ratio for death
was 1.03. Moreover, there were no signiﬁcant diﬀerences in
recurrence-free survival between the two groups.
Recently, meta-analyses of D2 lymphadenectomy versus
D2 with PAND were reported [28]. Three RCTs including
the PGCSG study in Poland [29], EASOG study in Japan,
Korea, and Chinese Taiwan area [30, 31], and JCOG-
9501 study in Japan [27]w e r ee l i g i b l e( Table 5). Another
analysis included 4 RCTs and 4 nonrandomized studies were
identiﬁed[32].These meta-analyses showed thatD2+PAND
canbeperformedassafelyasastandardD2resectionwithout
increasing postoperative mortality but failed to beneﬁt
overall survival in patients with advanced gastric cancer.
Gastrectomy with D2 lymphadenectomy plus PAND
cannot berecommendedas aroutinepracticeforthesurgical
treatment of gastric cancer.
5.MediastinalLymphNode Dissectionfor
GastricCancer
For patients with esophageal invasion from gastric cancer,
it is necessary to perform mediastinal resection included
the lower esophagus and the periesophageal lymph nodes
and to conﬁrm that the esophageal cut end is negative by
performing histological examination using frozen section as
necessary [33]. Conventionally, this mediastinal procedure
was done through the left thoracoabdominal approach
(LTA), because the frequency of lymph node metastasis was
reported to be high with about 20–40% and an adequate
margin from the tumor could be secured. However, a
mediastinal procedure was enabled through the abdominal-
transhiatal approach (TH) with advances in surgical meth-
ods using a circular stapler in recent years.
In Japan, an RCT comparing LTA versus TH for Siewert
type II and III tumors with esophageal invasion of 3cm
or less was carried out by JCOG [34]. Between 1995 and
2003, 167 patients were enrolled from 27 Japanese hospitals
and randomly assigned to TH (n = 82) or LTA (n = 85),
although the projected sample size was 302. After the ﬁrst
interim analysis, the predicted probability of LTA having
a signiﬁcantly better overall survival than TH at the ﬁnal
analysis was only 3.65%; therefore, the trial was closed. The
5-year overall survival was 52.3% in the TH group and
37.9% in the LTA group. The hazard ratio of death for
LTA compared with TH was 1.36 (0.89–2.08, P = .92).
Three patients died in hospital after LTA but none after TH.
Morbidity after LTA was worse than that after TH with rates
of 49% and 34%, respectively.
This study concluded that LTA could not be performed
for gastric cancer with esophageal invasion of 3cm or less,
because LTA did not improve survival compared to TH and
resulted in increased morbidity.
6.SplenectomyorPancreaticosplenectomy
inthe TreatmentofCancerofthe Upper
Third ofthe Stomach
In Japan, pancreaticosplenectomy for LN dissection around
the splenic artery (station no. 11) and splenic hilus (station
no. 10) had been widely performed, because this procedure
was proposed as a radical dissection of metastatic LN along
the splenic artery [35, 36]. However, Japanese retrospective
analyses proved that there was no survival beneﬁt of these6 International Journal of Surgical Oncology
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Figure 2: Lymph node dissection according to the Japanesegastric cancer treatment guideline 2010 ofthe 3rd edition reproduced form [14]
with permission. D1 distal gastrectomy consists of LN dissection of station nos. 1, 3, 4sb, 4d, 5, 6, and 7 and D1 total gastrectomy consistsof
station nos. 1–6 and 7 (blue circle). Yellow circles indicate the lymph nodes that belong to D1+, and red circles indicate those to D2.
procedures [37, 38]. Recently, pancreas-preserving splenec-
tomy has been considered a safe and eﬀective procedure
without decreasing surgical curability [39, 40].
In the JCOG 9501 study, pancreas-preserving splenec-
tomy was generally performed with low surgical mortality
[27, 41]. In this study, only 22 of 523 patients underwent
pancreaticosplenectomy and 59% of patients (13 of 22 cases)
developed postoperative complications.
In this pancreas-preserving procedure, the splenic artery
is generally divided at the distal site after branching-oﬀ
of the great pancreatic artery in Sasako’s modiﬁcation and
the splenic vein is preserved as distal as possible in order
to prevent pancreatic ﬁstula and pancreatic atrophy and
consequent glucose intolerance [42].
In Western countries as well, pancreaticosplenectomy
hada marked adverseeﬀectonbothmortality and morbidity
in two RCTs [5, 6].
Currently, pancreaticosplenectomy is considered beneﬁ-
cial only when the primary tumor or metastatic LN directly
invades the pancreas, but is not performed for prophylactic
dissection of lymph nodes around the splenic artery (station
no. 11).
According to the Japanese experience with LN dissection
at the splenic hilus with splenectomy, the incidence of hilar
node metastasis ranged 15–21% for tumors located at or
inﬁltrate to the proximal third of the stomach. About 20–
25%ofpatientswithLNmetastasishavesurvivedover5years
following LN dissection with splenectomy [35]. However,
hilar nodal metastasis was reported to be not found in
the early gastric cancer base on retrospective data [43, 44].
Splenectomy is recommended for curative resection of the
proximal advanced gastric cancer with inﬁltration to the
greatercurvatureintheGastric CancerTreatmentGuidelines
2010 [14].
Two RCTs compared gastrectomy with splenectomy and
gastrectomy alone in patients with gastric cancer were
reported with regard to the eﬀectiveness and safety [45, 46].
Csendes et al. reported 187 patients who underwent total
gastrectomy between 1985 and 1992; these patients were
randomized into two groups, gastrectomy with splenectomy
and gastrectomy alone. Postoperative complications were
more frequent in the splenectomy group than in the surgery
alone group, including postoperative fever over 38◦C (50%
versus 39%: P<. 04), pulmonary complications (39% versus
24%: P<. 008), and subphrenic abscess (11% versus 4%:
P<. 05). There were no signiﬁcant diﬀerences between the
groups in hospital mortality (4.4% for splenectomy versus
3.1% for gastrectomy alone) or in the 5-year survival rate
(42% for splenectomy versus 36% for gastrectomy alone)
[45].
The other trial reported by Yu et al. was carried out in
Korea between 1995 and 1999. Two hundred seven patients
with gastric cancer were divided randomly into two groups,
total gastrectomy (103 patients) and total gastrectomy plus
splenectomy (104 patients). Postoperative mortality was
8.7% in total gastrectomy alone group and 15.4% in total
gastrectomy plus splenectomy group, but there was no
signiﬁcant diﬀerence between the groups. Hospital mortality
was 1.0% in total gastrectomy alone and 1.9% in total
gastrectomy plussplenectomygroup;therewasnosigniﬁcant
diﬀerence between the two groups.
The 5-year survival rates did not diﬀer statistically
between the gastrectomy alone group (48.8%) and gastrec-
tomy plus splenectomy group (54.8%). There was no 5-year
survivor among patients with lymph node metastasis at the
splenic hilum in either group [46].
Therefore, these results did not support the eﬀectiveness
of prophylactic dissection at the splenic hilum duringInternational Journal of Surgical Oncology 7
splenectomy in patients undergoing total gastrectomy for
proximal gastric cancer.
7.FuturePerspectives
In Japan and Korea, gastrectomy with D2 LN dissection
is the gold standard of treatment for advanced gastric
cancer. In order to improve the prognosis of these patients,
adjuvant chemotherapy after D2 gastrectomy is thought
to be eﬀective and several studies have been reported
[47, 48]. Recently, a meta-analysis based on the individual
data of 3838 patients from 17 diﬀerent trials with median
follow-up 7 years was reported and indicated a modest
but statistically signiﬁcant beneﬁt associated with adjuvant
chemotherapy after curative resection of gastric cancer [49].
In Japan, adjuvant chemotherapy with S-1 is a standard
treatment for patients with stage II/III gastric cancer after
curative gastrectomy with D2 LN dissection [48]. Moreover,
to improve the survival of patients with advanced gastric
cancer, neoadjuvant chemotherapy and/or chemotherapy
with combination setting or new agents, such as molecular
targeting agents, are thought to be necessary in addition to
performing D2 gastrectomy with safety and reliability [50].
Last year, the Japanese Classiﬁcation of Gastric Carci-
noma was revised to conform with the TNM classiﬁcation
of UICC in many respects. In the new guidelines for the
Diagnosis and Treatment of Carcinoma of the Stomach,
D1, D1+, and D2 gastrectomy were described according to
the type of gastrectomy, making the guidelines easier to
understand. A global study using uniﬁed criteria is necessary
toestablishasafe andeﬀectiveworldwidetreatmentstandard
including gastrectomy with LN dissection.
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